Eight of 28 patients who received crizotinib treatment had c-MET amplification....Progression-free survival and overall survival in these eight patients were 9.4 and 10.9 months, respectively, and objective response rate was 50%....Crizotinib is an effective treatment option other than cytotoxic chemotherapy in the limited number of patients with MET amplification in the stage 4 lung adenocarcinoma subgroup.

Here, we report the case of an NSCLC patient with MET amplification whose disease was effectively controlled by crizotinib treatment...the immunohistochemistry analysis (IHC202101714) of the left lung puncture specimen revealed adenocarcinoma…the NGS genetic test results revealed MET copy number amplification....Targeted therapy with crizotinib 250 mg bid was continued....The patient did not experience any adverse events, such as abnormal liver function, during oral crizotinib therapy....Crizotinib showed good clinical efficacy in the MET-amplified NSCLC patient in this case...

An advanced lung adenocarcinoma patient with acquired resistance after EGFR TKI treatment, MET amplification was detected in plasma ctDNA. Patient accepted crizotinib and reached partial response.

The case harboring MET amplification of 10 copies achieved partial response and is one of the first MET-amplified lung cancer responsive to crizotinib in which the sole detection method was CGP.

A patient with lung adenocarcinoma with MCNG but without a high-level MET/CEP7 ratio or METex14 splicing mutations who achieved a rapid response to crizotinib, indicating that MCNG may be an independent predictive biomarker for response to MET inhibitors....Fluorescence in situ hybridization testing revealed a low MET/CEP7 ratio (1.21) but MCNG (6.7 copies per cell) based on counting 50 tumor cells within the area…he began to receive crizotinib. After oral administration for 25 days, the patient's chest pain eased and he achieved a partial response based on evaluation by chest computed tomograph.